| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1970) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| ATC: | L01XX23 |
| UNII: | 78E4J5IB5J |
Structure
| InChI Key | JWBOIMRXGHLCPP-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C14H10Cl4 |
| Molecular Weight | 320.05 |
| AlogP | 5.93 |
| Hydrogen Bond Acceptor | 0.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 0.0 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 18.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Cytochrome P450 11A1 inhibitor | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 108 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Carcinoma | 3 | D002277 | ClinicalTrials |
| Adrenal Cortex Neoplasms | 3 | D000306 | ClinicalTrials |
| Prostatic Neoplasms, Castration-Resistant | 1 | D064129 | ClinicalTrials |
Side Effects from Label
Side Effects (PT)
| Side effects | Relative Frequency (%) | Labels | |
|---|---|---|---|
| General disorders and administration site conditions Lethargy | 25.0 | ||
| Nervous system disorders Somnolence | 25.0 | ||
| Cardiac disorders Dizziness | 15.0 | ||
| Ear and labyrinth disorders Vertigo | 15.0 |
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 53-19-0 |
| ChEBI | 6954 |
| ChEMBL | CHEMBL1670 |
| DrugBank | DB00648 |
| DrugCentral | 1820 |
| EPA CompTox | DTXSID9020372 |
| FDA SRS | 78E4J5IB5J |
| Human Metabolome Database | HMDB0014786 |
| Guide to Pharmacology | 6957 |
| PharmGKB | PA164746157 |
| PubChem | 4211 |
| SureChEMBL | SCHEMBL4040 |
CONTENTS